Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
J Med Virol. 2023 Aug;95(8):e29031. doi: 10.1002/jmv.29031.
Omicron BF.7 became the predominant SARS-CoV-2 variant in Beijing after the abolishment of Zero-COVID policy in December 2022. The ability of antibodies elicited by BF.7 infection to cross-react with SARS-CoV-2-like viruses is unknown. This study aimed to investigate the cross-reactive neutralizing antibodies against SARS-CoV-2-related pangolin coronavirus GX_P2V in sera from vaccinated and/or SARS-CoV-2-infected individuals. All vaccinated individuals who recovered from Omicron BF.7 breakthrough infections exhibited substantially higher levels of neutralizing antibodies against GX_P2V, compared to other subject groups, with a geometric mean titer (GMT) of 362. Uninfected individuals who received four-mixed-dose vaccines also demonstrated higher levels of neutralizing antibodies (GMT = 44) against GX_P2V than those uninfected individuals who received two- or three-dose vaccines and those unvaccinated convalescents of wild-type SARS-CoV-2. This study highlights the significance of prior vaccinations with wild-type SARS-CoV-2 vaccines in generating potent cross-protective immunity against future spillovers of SARS-CoV-2-like viruses.
奥密克戎 BF.7 成为北京的主要 SARS-CoV-2 变体，自 2022 年 12 月取消“零新冠”政策以来。BF.7 感染引起的抗体与 SARS-CoV-2 样病毒发生交叉反应的能力尚不清楚。本研究旨在调查针对 SARS-CoV-2 相关穿山甲冠状病毒 GX_P2V 的接种和/或 SARS-CoV-2 感染个体血清中的交叉反应性中和抗体。所有从奥密克戎 BF.7 突破感染中恢复的接种者均表现出针对 GX_P2V 的中和抗体水平显著升高，与其他组相比，几何平均滴度（GMT）为 362。接受四价疫苗接种的未感染者也表现出针对 GX_P2V 的中和抗体水平高于接受两价或三价疫苗接种的未感染者和野生型 SARS-CoV-2 未感染者。这项研究强调了先前接种野生型 SARS-CoV-2 疫苗对产生针对未来 SARS-CoV-2 样病毒溢出的强大交叉保护免疫的重要性。
